Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position [Yahoo! Finance]
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
target on Rocket Pharmaceuticals to $8 from $10 and kept a Buy rating on the shares following an updated cash position that was made after the company announced its Q3 2025 update. In its Q3 2025 earnings report, Rocket Pharmaceuticals maintained a strong financial foundation, with cash, cash equivalents, and investments totaling ~$222.8 million as of the quarter end. This cash position is expected to provide an operational runway into Q2 2027, excluding potential future proceeds from a Priority Review Voucher/PRV that may be granted upon KRESLADI approval. The company also significantly reduced its net loss and operating expenses year-over-year. The net loss for Q3 was $50.3 million, or $0.45 per share (basic and diluted), a marked improvement from the Q3 2024 net loss of $66.7 million, or $0.71 per share. Rocket Pharmaceuticals achieved a critical milestone in its AAV cardiovascular gene therapy portfolio by successfully aligning with the FDA to lift the clinical hold on its piv
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals (NASDAQ:RCKT) was given a new $5.00 price target on by analysts at Morgan Stanley.MarketBeat
- Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals (NASDAQ:RCKT) was upgraded by analysts at TD Cowen to a "hold" rating.MarketBeat
- Rocket Pharmaceuticals Leads Our Trio Of Penny Stock Contenders [Yahoo! Finance]Yahoo! Finance
RCKT
Earnings
- 11/6/25 - Beat
RCKT
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/6/26 - Form 4
- 11/20/25 - Form 4
- RCKT's page on the SEC website